



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 10-100~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

of

Attorney Docket Number

Complete if Known

Application Number	10/621,054
Filing Date	July 15, 2003
First Named Inventor	Jan K. Caers
Art Unit	3761
Examiner Name	Catherine L. Anderson
Attorney Docket Number	ALLF0064-100 (17595 (BOT))

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Catharine Anderson/	Date Considered	08/17/2006
-----------------------	----------------------	--------------------	------------

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006, OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	2	of	2
		Complete if Known	
Application Number		10/621,054	
Filing Date		July 15, 2003	
First Named Inventor		Jan K. Caers	
Art Unit		3761	
Examiner Name		Catherine L. Anderson	
		Attorney Docket Number	
		ALLE0064-100 (17595 (BOT))	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
CA	AG	Argoff "A focused review of the use of botulinum toxins for neuropathic pain," <i>Clin J Pain</i> (2002) 18(6 Suppl):S177-S181.	
	AH	Cui et al., "Botulinum toxin type a (BTX-a) reduced inflammatory pain in the rat formalin model," <i>Cephalgia</i> (2000) 20(4):414.	
	AI	Cui et al., "Mechanisms of antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing," <i>Naunyn Schmiedebergs Arch Pharmacol</i> (2002) 265(Suppl 2):R17.	
	AJ	Duggan et al., "A survey of Botulinum neurotoxin substrate expression in cells," <i>Mov Disord</i> (1995) 10(3):376.	
	AK	Durham et al., "Mechanism of botulinum toxin type-A inhibition of calcitonin gene-related peptide secretion from trigeminal nerve cells," <i>Cephalgia</i> (2003) 23(7):690.	
	AL	Gonelle-Gispert et al., "SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion," <i>Biochem J</i> (1999) 339(pt 1):159-165.	
▼	AM	Ragona et al., "Management of parotid sialocele with botulinum toxin," <i>The Laryngoscope</i> (1999) 109(8):1344-1346.	

Examiner Signature	/Catharine Anderson/	Date Considered	08/17/2006
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.